Categories Uncategorized

Canadian Government Gives Formal Response to Petition to Decriminalize Psychedelics

Officials of the federal government of Canada have given an official response to a petition that called for psychedelic decriminalization in the country. The statement highlighted that there were various ways for some individuals to obtain exemptions to consume the substances legally, despite the drugs being illegal for the Canadian majority.

Government ministers stated that the psychedelic substances had to be studied more before any reforms were made. The petition, which garnered almost 15,000 signatures, was launched on the House of Commons’ site earlier this summer. The appeal requested legislators to decriminalize entheogenic fungi and plants to be used in various therapeutic practices, including healing ceremonies, as well as medical care.

Typically petitions have a 500-signature threshold, so by getting almost 30 times the number of signatures required, this proposal qualified to be presented to Parliament, with the government required to respond within 45 days. The petition was also read before the House of Commons on Sept. 30, 2020. The formal response from the government was announced last week.

The petition also calls for the government to respect the cultural and historical traditions around psychedelics. This would be done by the discontinuation of the enforcement of regulations or statutes that ban or impose heavy restrictions on adult use as well as the sharing or growing of any fungi or plant, particularly with regard to traditional use.

Ministers of Public Safety and Emergency Preparedness, Health and Justice all issued statements. Despite two of the statements admitting that there are opportunities for solitary exemptions under the CDSA for specific types of drug use, all statements re-emphasize that the trafficking and possession as well as the manufacture of psychedelic substances are still illegal acts.

Psychedelic substances are required to be approved by Canada’s drug review process and be authorized by Health Canada before they can be used as a mainstream therapeutic.

David Lametti, the attorney general, stated that the law provided the Minister of Health with the power to grant exemptions from the Controlled Drugs and Substances Act for scientific, medical and other public interest purposes. The latter included the protection of fundamental freedoms, such as the freedom of peaceful assembly, expression and religion. Lametti added that the extensive decriminalization petition wouldn’t comply with Canada’s agreement with international drug conventions, which include the Psychotropic Substances UN Convention 1971.

There is hope, however. In September, Patty Hajdu, Canadian health minister, gave four cancer patients an exemption that would allow them to have their end-of-life care include the use of psychedelic mushrooms.

The psychedelic and functional mushrooms sector in Canada is witnessing a growth spurt. Cybin Inc. (NEO: CYBN) is one of the key players in this industry, and its management team, which has an impressive list of clinical studies under their belt, is poised to make the company a leader in the psychedelic medicines and related products space.

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

4 days ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals is advancing a pipeline of innovative therapies targeting multibillion-dollar unmet needs in central…

4 weeks ago

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of…

4 weeks ago